Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
FBIO 
Fortress Biotech Inc (FBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/25/2025: FBIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -86.32% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/25/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 49.03M USD | Price to earnings Ratio - | 1Y Target Price 15.33 |
Price to earnings Ratio - | 1Y Target Price 15.33 | ||
Volume (30-day avg) 357888 | Beta 1.83 | 52 Weeks Range 1.33 - 2.89 | Updated Date 04/25/2025 |
52 Weeks Range 1.33 - 2.89 | Updated Date 04/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-26 | When Before Market | Estimate -0.75 | Actual -0.2993 |
Profitability
Profit Margin -79.75% | Operating Margin (TTM) -126.32% |
Management Effectiveness
Return on Assets (TTM) -41.3% | Return on Equity (TTM) -1739.64% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 67726174 | Price to Sales(TTM) 0.85 |
Enterprise Value 67726174 | Price to Sales(TTM) 0.85 | ||
Enterprise Value to Revenue 1.17 | Enterprise Value to EBITDA -0.29 | Shares Outstanding 29533800 | Shares Floating 20479355 |
Shares Outstanding 29533800 | Shares Floating 20479355 | ||
Percent Insiders 26.44 | Percent Institutions 16.55 |
Analyst Ratings
Rating 4.33 | Target Price 14 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Fortress Biotech Inc
Company Overview
History and Background
Fortress Biotech Inc. was founded in 2006. It is a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products.
Core Business Areas
- Drug Development: Focuses on acquiring and developing pharmaceutical and biotechnology products and product candidates.
- Commercialization: Commercializes approved products through its commercial subsidiaries.
- Subsidiary Management: Fortress manages and provides funding for its subsidiary companies, each with a specific therapeutic focus.
Leadership and Structure
Lindsay A. Rosenwald, M.D. serves as Chairman, President and CEO. The company has a board of directors and several executive officers overseeing various departments.
Top Products and Market Share
Key Offerings
- Description of Product 1, include any market share data or number of users or revenue from this product. Who are the competitors for this product]:
- Product Name 1: Dermatology Products (e.g., Accutane): Market share data unavailable. Competitors include Teva Pharmaceutical Industries (TEVA), Sun Pharmaceutical Industries (SUNPHARMA.NS). Revenues for the dermatology segment are not broken out precisely by Fortress.
- Description of Product 2, include any market share data or number of users or revenue from this product. Who are the competitors for this product]:
- Product Name 2: COSMC (cutaneous oncologic therapies): No definitive market share data available as it is in development. Competitors include companies developing similar therapies, such as those from Merck (MRK) and Bristol Myers Squibb (BMY).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and characterized by rapid technological advancements and intense research and development efforts.
Positioning
Fortress Biotech positions itself as a company that acquires and develops promising drugs and leverages a diversified portfolio of subsidiaries.
Total Addressable Market (TAM)
The TAM for the biopharmaceutical market is in the trillions of dollars globally. Fortress Biotech aims to capture a share of specific niche markets through its targeted therapies. Market value of the dermatology sector estimated at > $20 billion worldwide.
Upturn SWOT Analysis
Strengths
- Diversified portfolio of subsidiary companies
- Focus on acquiring and developing promising drug candidates
- Experienced management team
- Strategic relationships with academic institutions
Weaknesses
- Reliance on raising capital to fund operations
- Dependence on the success of its subsidiary companies
- Risk of clinical trial failures
- Relatively small market capitalization
Opportunities
- Potential for partnerships and collaborations
- Expansion into new therapeutic areas
- Acquisition of additional promising drug candidates
- Advancements in drug development technologies
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles and delays
- Patent expirations
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- TEVA
- MRK
- BMY
- VTRS
- SUNPHARMA.NS
Competitive Landscape
Fortress Biotech operates in a competitive landscape with larger, more established pharmaceutical companies. Its competitive advantage lies in its ability to acquire and develop promising drug candidates and leverage a diversified portfolio of subsidiary companies. Its size is a disadvantage.
Major Acquisitions
Avenue Therapeutics
- Year: 2016
- Acquisition Price (USD millions): 18.5
- Strategic Rationale: Expand portfolio with IV Tramadol, a pain medication.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on acquisitions and clinical trial successes. Performance is inconsistent.
Future Projections: Future projections are subject to the success of clinical trials and regulatory approvals. Analyst estimates are not consistently reliable.
Recent Initiatives: Recent initiatives include advancing clinical programs for its subsidiary companies and exploring new partnership opportunities.
Summary
Fortress Biotech is a biopharmaceutical company with a diversified portfolio of subsidiaries and drug candidates. Its strengths lie in its acquisition strategy and experienced management team. However, it faces challenges related to raising capital, clinical trial risks, and competition from larger pharmaceutical companies. The company's success is highly dependent on the progress of its clinical programs and regulatory approvals.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
TEVA
Teva Pharma Industries Ltd ADR
TEVA
Teva Pharma Industries Ltd ADR
VTRS
Viatris Inc
VTRS
Viatris Inc
XOMA
XOMA Corp
XOMA
XOMA Corp
Sources and Disclaimers
Data Sources:
- SEC filings
- Company website
- Analyst reports
- Third-party market research reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share data is estimated based on publicly available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fortress Biotech Inc
Exchange NASDAQ | Headquaters Bay Harbor Islands, FL, United States | ||
IPO Launch date 2011-11-17 | Executive Chairman, President & CEO Dr. Lindsay Allan Rosenwald | ||
Sector Healthcare | Industry Biotechnology | Full time employees 101 | Website https://www.fortressbiotech.com |
Full time employees 101 | Website https://www.fortressbiotech.com | ||
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Emrosi, a minocycline hydrochloride extended-release capsules; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first- and second-degree burns, including sunburns, and radiation dermatitis. It also develops late-stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; UNLOXCYT for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. The company's preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.